Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

NEW YORK, March 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

http://www.reportlinker.com/p0957407/Substance-Abuse-Therapeutics-Market-to-2018---Effective-Drug-Therapies-in-the-Treatment-of-Alcohol-and-Opioid-Dependence-Offer-Significant-Market-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

Summary

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the substance abuse therapeutics market in the top seven markets was valued at $8.8 billion in 2011, increasing at a CAGR of 4.9% during the review period 2004–2011. The market is projected to witness moderate growth of 5.3% during the 2011–2018 forecast period to reach $12.7 billion. The moderate growth of the market can be attributed to the presence of generics in the market, low compliance with therapy due to the nature of addiction and the lack of innovative products in the pipeline. However, indications such as cocaine addiction, which currently have no approved products, are expected to see entries to the market and high-priced products such as Champix for smoking cessation will not see patent expiry in the forecast period.

Scope

- Annualized market data for the substance abuse therapeutics market from 2004-2011 with forecasts to 2018.

- Market data on the therapeutic landscape, which covers nicotine addiction, alcohol dependence and opioid and cocaine abuse. This includes market size, annual cost of therapy, treatment flow algorithm.

- Key drivers and restraints that have had a significant impact on the market and on each indication.

- The competitive landscape of the global substance abuse therapeutics market, which includes companies such as Pfizer, GSK, Forest Laboratories, Alkermes and Reckitt Benckiser.

- Key M&A activities and licensing agreements that took place from 2007 to 2011 in the global substance abuse therapeutics market.

Reasons to buy

- Develop market-entry and market expansion strategies by identifying the potential region and substance abuse therapeutics market segments poised for strong growth.

- Create a more tailored country strategy through the understanding of key drivers and barriers of the global substance abuse therapeutics market.

- Develop key strategic initiatives by understanding the key focus areas and top selling therapeutics of leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

1 Table of Contents1 Table of Contents 51.1 List of Tables 81.2 List of Figures 102 Substance Abuse Therapeutics Market to 2018 - Introduction 122.1 Overview 123 Substance Abuse Therapeutics Market to 2018 - Market Overview 143.1 Introduction 143.2 Revenue Forecasts for Substance Abuse Therapeutics Market 143.2.1 Revenue 143.2.2 Annual Cost of Treatment 163.3 Treatment Usage Patterns 173.3.1 Diseased Population 173.3.2 Diagnosed Population 183.3.3 Prescription Population 193.4 Drivers and Barriers for Substance Abuse Therapeutics Market 203.4.1 Drivers 203.4.2 Barriers 214 Substance Abuse Therapeutics Market to 2018 - Geographical Landscape 224.1 The US 224.1.1 Revenue 224.1.2 Annual Cost of Treatment 234.1.3 Treatment Usage Patterns 244.1.4 Diagnosed Population 254.1.5 Prescription Population 264.2 Top Five Countries of Europe 274.2.1 Revenue 274.2.2 Annual Cost of Treatment 284.2.3 Treatment Usage Patterns 294.3 Japan 324.3.1 Revenue 324.3.2 Annual Cost of Treatment 344.3.3 Treatment Usage Patterns 355 Substance Abuse Therapeutics Market to 2018 - Nicotine Addiction Therapeutics Market 385.1 Introduction 385.1.1 Treatment Flow Algorithm 395.1.2 Opportunities/Unmet Needs 395.1.3 Revenue 405.1.4 Annual Cost of Treatment 425.1.5 Treatment Usage Patterns 435.1.6 Drivers and Barriers for the Nicotine Addiction Market 465.1.7 Drivers 465.1.8 Barriers 475.2 Marketed Products 485.2.1 Chantix (varenicline) 485.2.2 Zyban (buproprion hydrochloride) 485.2.3 Nicotine Replacement Therapies 486 Substance Abuse Therapeutics Market to 2018 - Alcohol Dependence Therapeutics Market 506.1 Introduction 506.1.1 Treatment Flow 516.1.2 Opportunities/Unmet Needs 526.1.3 Revenue 526.1.4 Annual Cost of Treatment 546.1.5 Treatment Usage Patterns 556.2 Drivers and Barriers for Alcohol Dependence Therapeutic Market 586.2.1 Drivers 586.2.2 Barriers 596.3 Marketed Products 596.3.1 Detoxification treatment options 596.3.2 Campral (acamprosate calcium) 596.3.3 Antabuse (disulfurum) 606.3.4 Vivitrol (naltrexone) 607 Substance Abuse Therapeutics Market to 2018 - Drug Abuse Therapeutics Market 617.1 Introduction 617.1.1 Opioid Abuse 617.1.2 Cocaine Abuse 627.1.3 Treatment Flow Algorithm 627.1.4 Opportunities/Unmet Needs 637.2 Revenues 637.2.1 Annual Cost of Therapy 657.2.2 Treatment Usage Patterns 667.3 Drivers and Barriers for Drug Abuse 697.3.1 Drivers 697.3.2 Barriers 697.4 Marketed Drugs - Opioid Abuse 707.4.1 Methadone 707.4.2 Suboxone (buprenorphine and naloxone) 707.4.3 Buprenorphine Hydrochloride 707.4.4 Vivitrol (naltrexone) 707.5 Marketed Products - Cocaine Abuse 707.5.1 Overview 707.5.2 Sabril (vigabatrin) 707.5.3 Fluoxetine 717.5.4 Disulfiram (Antabuse) 717.5.5 Naltrexone 717.5.6 Topiramate 717.5.7 Amantadine 717.5.8 Baclofen 717.5.9 Modafinil 718 Substance Abuse Therapeutics Market to 2018 - Product Pipeline Analysis 728.1 R&D Pipeline - Nicotine Addiction Therapeutics Market 728.1.1 Pre-clinical and Discovery Phase 728.1.2 Phase I 728.1.3 Phase II 728.1.4 Promising Pipeline Molecules 728.2 R&D Pipeline - Alcohol Dependence Therapeutics Market 738.2.1 Pre-clinical and Discovery Phase 738.2.2 Phase I 738.2.3 Phase II 738.2.4 NDA Filed 738.2.5 Promising Molecules in the Pipeline 748.2.6 NS11 748.3 R&D Pipeline - Drug Abuse Therapeutics Market 758.3.1 Pre-clinical and Discovery Phase 758.3.2 Phase I 758.3.3 Phase II 758.3.4 Phase III 758.3.5 Promising Molecules in the Pipeline 769 Substance Abuse Therapeutics Market to 2018 - Competitive Landscape 779.1 GlaxoSmithKline 779.1.1 Overview 779.1.2 Major Products in the Substance Abuse Therapeutics Market 779.1.3 SWOT Analysis 789.2 Pfizer 789.2.1 Overview 789.2.2 Major Products in the Substance Abuse Therapeutics Market 789.2.3 SWOT Analysis 799.3 Alkermes 809.3.1 Overview 809.3.2 Major Products in the Substance Abuse Therapeutics Market 809.3.3 SWOT Analysis 809.4 Forest Laboratories, Inc. 819.4.1 Overview 819.4.2 Major Products in the Substance Abuse Therapeutics Market 819.4.3 SWOT Analysis 819.5 Teva Pharmaceuticals 829.5.1 Overview 829.5.2 Major Products in the Substance Abuse Therapeutics Market 829.5.3 SWOT Analysis 829.6 Reckitt Benckiser Pharmaceuticals 839.6.1 Overview 839.6.2 Major Products in the Substance Abuse Therapeutics Market 839.6.3 SWOT Analysis 8410 Substance Abuse Therapeutics Market to 2018 - Strategic Consolidations 8510.1 Mergers and Acquisitions (M&A) 8510.1.1 Deals by Year 8510.1.2 Deals by Geography 8610.1.3 Major Mergers and Acquisitions, 2007-2012 8610.2 Licensing Agreements 8710.2.1 Deals by Year 8710.2.2 Deals by Geography 8810.2.3 Major Licensing and Co-Development Agreements, 2007-2012 8811 Substance Abuse Therapeutics Market to 2018 - Appendix 9011.1 Market Definitions 9011.2 Abbreviations 9011.3 Bibliography 9111.4 Research Methodology 9311.4.1 Coverage 9311.4.2 Secondary Research 9311.4.3 Primary Research 9311.5 Therapeutic Landscape 9411.5.1 Epidemiology-based Forecasting 9411.5.2 Market Size by Geography 9611.6 Geographical Landscape 9711.7 Pipeline Analysis 9711.8 Competitive Landscape 9711.8.1 Expert Panel Validation 9711.9 Contact Us 9711.10 Disclaimer 97

1.1 List of Tables

Table 1: Substance Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2011 15

Table 2: Substance Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 15

Table 3: Substance Abuse Therapeutics Market, Global, ACT ($), 2004-2011 16

Table 4: Substance Abuse Therapeutics Market, Global, ACT ($), 2011-2018 16

Table 5: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2004-2011 17

Table 6: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2011-2018 17

Table 7: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 18

Table 8: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 18

Table 9: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2011 19

Table 10: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2011-2018 19

Table 11: Substance Abuse Therapeutics Market, The US, Revenue ($bn), 2004-2011 22

Table 12: Substance Abuse Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018 22

Table 13: Substance Abuse Therapeutics Market, The US, ACT ($), 2004-2011 23

Table 14: Substance Abuse Therapeutics Market, The US, ACT ($), 2011-2018 23

Table 15: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2004-2011 24

Table 16: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2011-2018 24

Table 17: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2004-2011 25

Table 18: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2011-2018 25

Table 19: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2004-2011 26

Table 20: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2011-2018 26

Table 21: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 27

Table 22: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 27

Table 23: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2004-2011 28

Table 24: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2011-2018 28

Table 25: Substance Abuse Therapeutics Market, Top Five Countries of Europe Diseased Population (millions), 2004-2011 29

Table 26: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diseased Population (millions), 2011-2018 29

Table 27: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2004-2011 30

Table 28: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2011-2018 31

Table 29: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2004-2011 31

Table 30: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2011-2018 32

Table 31: Substance Abuse Therapeutics Market, Japan, Revenue ($m), 2004-2011 32

Table 32: Substance Abuse Therapeutics Market, Japan, Revenue Forecasts ($m), 2011-2018 33

Table 33: Substance Abuse Therapeutics Market, Japan, ACT ($), 2004-2011 34

Table 34: Substance Abuse Therapeutics Market, Japan, ACT ($), 2011-2018 34

Table 35: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions), 2004-2011 35

Table 36: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions, 2011-2018 35

Table 37: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2004-2011 36

Table 38: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2011-2018 36

Table 39: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2004-2011 37

Table 40: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2011-2018 37

Table 41: Nicotine Addiction Therapeutics Market, Global, Revenue ($bn), 2004-2011 40

Table 42: Nicotine Addiction Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 40

Table 43: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2004-2011 42

Table 44: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2011-2018 42

Table 45: Nicotine Addiction Market, Global, Diseased Population (millions), 2004-2011 43

Table 46: Nicotine Addiction Therapeutics Market, Global, Diseased Population (millions), 2011-2018 43

Table 47: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 44

Table 48: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 44

Table 49: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2004-2011 45

Table 50: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2011-2018 45

Table 51: Alcohol Dependence Therapeutics Market, Global, Revenue ($m), 2004-2011 53

Table 52: Alcohol Dependence Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 53

Table 53: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2004-2011 54

Table 54: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2011-2018 54

Table 55: Alcohol Dependence Therapeutic Market, Global, Diseased Population (millions), 2004-2011 55

Table 56: Alcohol Dependence Therapeutic Market, Global, Diseased Population (millions), 2011-2018 55

Table 57: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 56

Table 58: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 56

Table 59: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000'), 2004-2011 57

Table 60: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000'), 2011-2018 57

Table 61: Drug Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2011 64

Table 62: Drug Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 64

Table 63: Drug Abuse Therapeutics Market, Global, Average ACT ($), 2004-2011 65

Table 64: Drug Abuse Therapeutics Market, Global, Average ACT ($), 2011-2018 65

Table 65: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2004-2011 66

Table 66: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2011-2018 66

Table 67: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 67

Table 68: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 67

Table 69: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2011 68

Table 70: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2011-2018 68

Table 71: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2011 72

Table 72: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Phase I, 2011 72

Table 73: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Phase II, 2011 72

Table 74: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2011 73

Table 75: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase I, 2011 73

Table 76: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase II, 2011 73

Table 77: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in NDA Filed, 2011 73

Table 78: Drug Abuse Therapeutics Market, Global, Pre-clinical, 2011 75

Table 79: Drug Abuse Therapeutics Market, Global, Phase I, 2011 75

Table 80: Drug Abuse Therapeutics Market, Global, Phase II, 2011 75

Table 81: Drug Abuse Therapeutics Market, Global, Phase III, 2011 75

1.2 List of Figures

Figure 1: Substance Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 14Figure 2: Substance Abuse Therapeutics Market, Global, ACT ($), 2004-2018 16Figure 3: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2004-2018 17Figure 4: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 18Figure 5: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2018 19Figure 6: Substance Abuse Therapeutics Market, Drivers and Barriers, 2011 20Figure 7: Substance Abuse Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018 22Figure 8: Substance Abuse Therapeutics Market, The US, ACT ($), 2004-2018 23Figure 9: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2004-2018 24Figure 10: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2004-2018 25Figure 11: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2004-2018 26Figure 12: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2004-2018 27Figure 13: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2004-2018 28Figure 14: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diseased Population (millions), 2004-2018 29Figure 15: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2004-2018 30Figure 16: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2004-2018 31Figure 17: Substance Abuse Therapeutics Market, Japan, Revenue Forecasts ($m), 2004-2018 32Figure 18: Substance Abuse Therapeutics Market, Japan, ACT ($), 2004-2018 34Figure 19: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions), 2004-2018 35Figure 20: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2004-2018 36Figure 21: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2004-2018 37Figure 22: Nicotine Addiction Therapeutics Market, Treatment Flow Algorithm 39Figure 23: Nicotine Addiction Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 40Figure 24: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2004-2018 42Figure 25: Nicotine Addiction Therapeutics Market, Global, Diseased Population (millions), 2004-2018 43Figure 26: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 44Figure 27: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2004-2018 45Figure 28: Nicotine Addiction Therapeutics Market, Global, Drivers and Barriers, 2011 46Figure 29: Alcohol Dependence Therapeutics Market, Treatment Flow Algorithm 51Figure 30: Alcohol Dependence Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018 52Figure 31: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2004-2018 54Figure 32: Alcohol Dependence Therapeutics Market, Global, Diseased Population (millions), 2004-2018 55Figure 33: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 56Figure 34: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000'), 2004-2018 57Figure 35: Alcohol Dependence Therapeutics Market, Global, Drivers and Barriers, 2011 58Figure 36: Drug Abuse Therapeutics Market, Treatment Flow Algorithm 62Figure 37: Drug Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2018 63Figure 38: Drug Abuse Therapeutics Market, Global, ACT ($), 2004-2018 65Figure 39: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2004-2018 66Figure 40: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 67Figure 41: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2018 68Figure 42: Drug Abuse Therapeutics Market, Global, Drivers and Barriers, 2011 69Figure 43: Substance Abuse Therapeutics Market, SWOT Analysis, GSK, 2011 78Figure 44: Substance Abuse Therapeutics Market, SWOT Analysis, Pfizer, 2011 79Figure 45: Substance Abuse Therapeutics Market, SWOT Analysis, Alkermes, 2011 80Figure 46: Substance Abuse Therapeutics Market, SWOT Analysis, Forest Laboratories Inc., 2011 81Figure 47: Substance Abuse Therapeutics Market, SWOT Analysis, Teva Pharmaceutical, 2011 82Figure 48: Substance Abuse Therapeutics Market, SWOT Analysis, Reckitt Benckiser, 2011 84Figure 49: Substance Abuse Therapeutics Market, Global, Major M&A Deals By Year, 2007-2012 85Figure 50: Substance Abuse Therapeutics Market, Global, Major M&A Deals By Geography, 2007-2012 86Figure 51: Substance Abuse Therapeutics Market, Global, R&D Licensing Deals By Year, 2007-2012 87Figure 52: Substance Abuse Therapeutics Market, Global, Major R&D Licensing Deals By Geography, 2007-2012 88Figure 53: GBI Research Market Forecasting Model 96

Companies mentioned

GlaxoSmithKline

Pfizer

Alkermes

Forest Laboratories, Inc.

Teva Pharmaceuticals

Reckitt Benckiser Pharmaceuticals

To order this report:: Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

Contact Clare: [email protected]

US:(339) 368 6001

Intl:+1 339 368 6001

SOURCE Reportlinker